TCTR20220901002Unknown3 期
Efficacy of Monoclonal Neutralizing Antibody AZD 7442 (Tixagevimab-Cilgavimab for prevention of COVID-19 among cancer patients: Double blinded Randomized placebo Controlled Trial (ProvMAB Trial)
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 N/A (No limit)（—）
- 性别
- All
入选标准
- •1. Low-risk patients or high-risk groups aged 18 years and over.
- •2. Weight greater than or equal to 40 kg.
- •3. Patients with Hematologic malignancy, breast cancer, lung cancer and colon cancer. who are receiving cancer treatment or have been treated for cancer within 6 months from the date of study (by assessing survival for more than 6 months).
- •People who have received at least 3 doses of Covid-19 vaccine and received the latest dose of vaccine for more than 2 weeks and not more than 3 months.
- •5. Understand Thai language and be able to communicate with the researcher to assess side effects from treatment. Able to use communication technology equipment
- •6. Can be monitored
- •7. Consent and sign to participate in the research
排除标准
- •1. Pregnant or lactating women
- •2. Infected with Coronavirus 2019 within 3 months before participating in the research.
- •3. Has hepatic disease (child C) or end-stage renal disease (ESRD not on hemodialysis or not on hemodialysis at least twice a week).
- •4. Metastatic or terminal cancer (by assessing survival time less than 3 months)
- •5. Patients who are bedridden and unable to be treated are outpatients.
- •6. Previously received other neutralizing monoclonal antibody drugs within 60 days.
- •7. People who have had an allergic reaction to Tixagevimab/Cilgavimab.
- •8. People who have received the latest dose of Covid-19 vaccine for more than 3 months.
研究者
相似试验
尚未招募
1 期
imotuzumab in COVID-19COVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusAcute DiseaseCritical CareRPCEC00000369Center of Molecular Immunology (CIM)40
尚未招募
1 期
imotuzumab cold kit for the immunodiagnosis of solid tumorsLung DiseasesTumors of head and neck, lung and gliomasHead and Neck NeoplasmsLung NeoplasmsRespiratory Tract NeoplasmsThoracic NeoplasmsGliomaRespiratory Tract DiseasesNeoplasms, NeuroepitheliaNeoplasms, Glandular and EpithelialNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueNeuroectodermal TumorsRPCEC00000290Center of Molecular Immunology (CIM)
已完成
不适用
The Outcome of Neutralizing Monoclonal Antibodies versus Favipiravir Treatment among Mild to Moderate COVID-19 in Middle-aged Patients and Special Populations in Outpatient ClinicMild to moderate COVID-19 in those aged 40-60 years, elderly, diabetes mellitus and obesityCOVID-19, favipiravir, monoclonal antibody, SARS-CoV-2, treatmentTCTR20230912002Chulabhorn Royal Academy1,410
招募中
1 期
Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaRelapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/LymphomaMedDRA version: 21.1Level: LLTClassification code: 10066110Term: T-cell lymphoblastic leukemia acute Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10042971Term: T-cell lymphoma Class: 100000004864CTIS2023-508355-39-00Ospedale Pediatrico Bambino Gesu'26
招募中
不适用
Efficacy of a novel experimental antibody in a humanized mouse model of psoriasisflaking diseasepsoriasis1000381610014982NL-OMON34037Boehringer Ingelheim24